Recent research has expanded on the extensive inflammatory-resolving benefits of Hofseth BioCare’s full spectrum of 21 omegas and fatty acids ingredient OmeGo®.
The study, published in Biomedical, found the antioxidant action of OmeGo® helped to resolve type 1 inflammation induced by injury or irritant. These latest findings complement previous work by Hofseth BioCare (HBC), which highlighted the ability of OmeGo® to significantly reduce type 2 allergic inflammation.
A preliminary animal model was undertaken to determine OmeGo®’s impact on swelling compared to non-steroidal anti-inflammatory drug (NSAID) diclofenac, which is widely used in the management of inflammatory conditions and pain.
Over the 24-hour period of the study, OmeGo® showed a similar impact on swelling as diclofenac, while avoiding the side effects commonly associated with prolonged use of NSAIDs, such as gastrointestinal ulceration and increased cardiovascular risk.
Further work is planned to characterise OmeGo®’s modulation of inflammatory pathways and its potential as a pragmatic approach to help resolve acute inflammation and aid tissue injury repair.
OmeGo® is enzymatically liberated from fresh Atlantic salmon and is a close proxy for consuming whole fish. Minimally processed with low levels of oxidation, it contains all of the polyunsaturated acids found in fish, not just omega-3.
“Consumption of whole, fresh fish is linked to better health, including a reduction in cardiovascular events, through important underlying inflammation-resolving effects,” said Dr. Crawford Currie, Head of Medical R&D at Hofseth BioCare.
“OmeGo® goes beyond standard omega-3 supplementation, with nothing added, nothing taken away, nothing compromised.
“These findings build on existing evidence that this effective nutritional ingredient can offer a natural and safe approach to achieving optimal wellbeing, by encapsulating all the health benefits of whole, fresh fish, without the health drawbacks, such as seen with long-term NSAIDs use.”
OmeGo®’s capabilities are the subject of ongoing studies in a range of health areas, including heart health, Covid, asthma, COPD and joint health.
Further to the clinical research, OmeGo®, which is classified as a New Dietary Ingredient (NDI) by the US Food & Drug Administration (FDA), recently achieved 22 US FDA Structure Function Claims, some of which are unique to HBC.
Eight of the new claims relate to heart health, including support of vascular health, circulation, and healthy cholesterol levels. OmeGo® has also gained new claims in joint health – more specifically healthy inflammatory response to exercise – and in supporting brain function, cognitive health and eye health.
In addition to this, OmeGo® has achieved specific and unique FDA claims, including helping to support cardiovascular health and to sustain a healthy oxidative balance, thanks to potent antioxidant properties not present in processed fish oils.
Further studies are in the pipeline to assess the potential positive effects of OmeGo® on gut health, immunity, and pollution-induced inflammation.
“With OmeGo®, the possibilities are almost endless,” added Dr Currie. “Our burgeoning bank of scientific evidence, backed by a growing list of credible health claims, adds credence to what we already know – that OmeGo® is the closest we can get to eating fresh, whole fish and to reaping the full breadth of its intrinsic and clinically-important health benefits.
“Unmatched in the market, OmeGo® is truly transformative ingredient for nutraceutical manufacturers and brand owners and we are excited to further elucidating its vast and varied health benefit profile.”
For more information, please find the full scientific study here or contact the Hofseth BioCare team here: Hofseth BioCare | Research and development.